Modern Chinese Medicine Group
Market Cap
HK$486.0m
Last Updated
2021/04/11 10:26 UTC
Data Sources
Company Financials
Executive Summary
Modern Chinese Medicine Group Co. Ltd. produces and sells Chinese medicines. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with acceptable track record.
Share Price & News
How has Modern Chinese Medicine Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1643 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: Insufficient data to determine 1643's volatility change over the past year.
Market Performance
7 Day Return
-5.8%
1643
0.8%
HK Pharmaceuticals
-1.1%
HK Market
1 Year Return
n/a
1643
21.2%
HK Pharmaceuticals
28.6%
HK Market
Return vs Industry: Insufficient data to determine how 1643 performed against the Hong Kong Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 1643 performed against the Hong Kong Market.
Shareholder returns
| 1643 | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.8% | 0.8% | -1.1% |
| 30 Day | -4.7% | 0.7% | -1.8% |
| 90 Day | n/a | 10.0% | 3.4% |
| 1 Year | n/a | 23.0%21.2% | 33.5%28.6% |
| 3 Year | n/a | -14.3%-19.1% | 4.0%-6.9% |
| 5 Year | n/a | 79.2%62.4% | 48.7%23.7% |
Long-Term Price Volatility Vs. Market
How volatile is Modern Chinese Medicine Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Modern Chinese Medicine Group undervalued compared to its fair value and its price relative to the market?
4.83x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1643 (HK$0.81) is trading above our estimate of fair value (HK$0.61)
Significantly Below Fair Value: 1643 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1643 is good value based on its PE Ratio (4.8x) compared to the HK Pharmaceuticals industry average (12x).
PE vs Market: 1643 is good value based on its PE Ratio (4.8x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1643's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1643 is overvalued based on its PB Ratio (2.3x) compared to the HK Pharmaceuticals industry average (1.3x).
Future Growth
How is Modern Chinese Medicine Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
18.2%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Modern Chinese Medicine Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Modern Chinese Medicine Group performed over the past 5 years?
37.4%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 1643 has high quality earnings.
Growing Profit Margin: 1643's current net profit margins (20.6%) are lower than last year (21.1%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 1643's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare 1643's past year earnings growth to its 5-year average.
Earnings vs Industry: 1643 earnings growth over the past year (37.4%) exceeded the Pharmaceuticals industry 2.7%.
Return on Equity
High ROE: 1643's Return on Equity (47.2%) is considered outstanding.
Financial Health
How is Modern Chinese Medicine Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1643's short term assets (CN¥188.9M) exceed its short term liabilities (CN¥74.2M).
Long Term Liabilities: 1643's short term assets (CN¥188.9M) exceed its long term liabilities (CN¥203.0K).
Debt to Equity History and Analysis
Debt Level: 1643's debt to equity ratio (3.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 1643's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 1643's debt is well covered by operating cash flow (264.1%).
Interest Coverage: 1643's interest payments on its debt are well covered by EBIT (943.1x coverage).
Balance Sheet
Dividend
What is Modern Chinese Medicine Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1643's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1643's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1643's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1643's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1643's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Modern Chinese Medicine Group has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: 1643 only recently listed within the past 12 months.
Top Shareholders
Company Information
Modern Chinese Medicine Group Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Modern Chinese Medicine Group Co., Ltd.
- Ticker: 1643
- Exchange: SEHK
- Founded: 1986
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$486.000m
- Shares outstanding: 600.00m
- Website: https://www.cdysjdyy.com
Number of Employees
Location
- Modern Chinese Medicine Group Co., Ltd.
- 88 Jinwei Road
- Chengde
- Hebei Province
- 67000
- China
Listings
Biography
Modern Chinese Medicine Group Co. Ltd. produces and sells Chinese medicines. The company was founded in 1986 and is based in Chengde, China.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 10:26 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.